The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better treatment ...
Morning Overview on MSN
A gene therapy injected straight into brain tumors just began dosing its first patients — a virus engineered to kill glioblastoma cells and spare the rest
Somewhere in an operating room this spring, a neurosurgeon did something that has never been done before: while removing a ...
The development of efficient and safe delivery systems is a cornerstone of gene therapy and genome editing. Lipid nanoparticles (LNPs), adeno-associated ...
After a patient died following a high dose of Neurogene’s Rett syndrome gene therapy candidate, the biotech is sharing details about the event and the new safety protocols being incorporated into the ...
Research Describes the Potential of JCR’s Platform Technologies, Including JUST-AAV Gene Therapy, to Facilitate Delivery of Therapies to the Central Nervous System -HYOGO, Japan--(BUSINESS WIRE)--JCR ...
While the overwhelming scope of tragic outcomes from HIV infection at the origin of the AIDS epidemic are in the past, those living with HIV still require daily treatments. One option includes ...
USP recognizes CryoTEM for characterizing empty/full/intermediate capsids on AAV8 reference standards STOCKHOLM, ...
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results